Fetal Aneuploidy Confirmation Testing Market Forecast Covering Key Growth Drivers And Future Industry Trends
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Fetal Aneuploidy Confirmation Testing Market Between 2026 And 2030?
The fetal aneuploidy confirmation testing market has experienced swift growth in recent years. Projections show that it is expected to increase from $1.43 billion in 2025 to $1.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. Key drivers of this past growth include an uptick in pregnancies at advanced maternal ages, the escalating prevalence of chromosomal abnormalities, enhanced public knowledge of prenatal screening initiatives, improvements in cytogenetic testing procedures, and the broadened availability of diagnostic facilities in hospitals.
The fetal aneuploidy confirmation testing market size is projected to experience rapid expansion in the coming years. It is expected to grow to $2.36 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.6%. The anticipated growth during this period stems from factors such as the increasing adoption of precision medicine approaches, the growing integration of AI-based genetic analysis tools, a rising demand for non-invasive prenatal testing confirmation, the expansion of genomic research initiatives, and increasing healthcare infrastructure investments in emerging markets. Key trends foreseen over the forecast horizon include the increasing adoption of next-generation sequencing technologies, a rising demand for early and accurate prenatal diagnosis, a growing preference for confirmatory diagnostic testing after positive screening, the expansion of advanced chromosomal microarray analysis, and an increasing availability of specialized prenatal diagnostic services.
Access Your Free Sample Report For In-Depth Market Analysis:
What Leading Drivers Are Supporting The Fetal Aneuploidy Confirmation Testing Market Expansion?
The increasing maternal age is projected to stimulate the expansion of the fetal aneuploidy confirmation testing market in the future. Maternal age denotes a woman’s age when she becomes pregnant or gives birth. This age is rising because women are postponing parenthood to focus on higher education and career progression before starting families. Fetal aneuploidy confirmation testing plays a role in addressing the risks tied to advancing maternal age by precisely verifying chromosomal abnormalities, which are more prevalent in pregnancies among older women, thereby facilitating prompt medical guidance and knowledgeable pregnancy choices. For example, in June 2025, data from the Centers for Disease Control and Prevention, a US-based government agency, showed that the average age of mothers at first birth rose from 27.4 years in 2022 to 27.5 years in 2023, an increase of 0.1 years. Hence, the increasing maternal age is fueling the growth of the fetal aneuploidy confirmation testing market. The expansion of personalized medicine is anticipated to fuel the growth of the fetal aneuploidy confirmation testing market moving forward. Personalized medicine is a healthcare methodology that customizes prevention, diagnosis, and treatment strategies to an individual’s distinct genetic makeup, biomarkers, and molecular characteristics. This field is advancing due to rapid progress in genomic technologies and biomarker-based diagnostics, which enable medical professionals to tailor treatments and interventions to a patient’s unique genetic profile. Fetal aneuploidy confirmation testing facilitates personalized medicine by providing precise genetic information about the fetus, allowing clinicians to customize prenatal care, risk management, and treatment decisions specifically to the individual genetic profile of each pregnancy. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases, a significant increase from the six approvals recorded in 2022. Hence, the growth in personalized medicine is driving the growth of the fetal aneuploidy confirmation testing market.
Which Segment Categories Are Included In The Fetal Aneuploidy Confirmation Testing Market Segment Analysis?
The fetal aneuploidy confirmation testing market covered in this report is segmented –
1) By Test Type: Non-Invasive Prenatal Testing, Invasive Testing, Other Test Types
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Microarray, Other Technologies
3) By Application: Trisomy, Sex Chromosome Aneuploidy, Microdeletions, Other Applications
4) By End-User: Hospitals, Diagnostic Laboratories, Specialty Clinics, Other End Users
Subsegments:
1) By Non-Invasive Prenatal Testing: Cell-Free Fetal Deoxyribonucleic Acid Testing, Maternal Serum Screening, Ultrasound-Based Risk Assessment, Next-Generation Sequencing-Based Non-Invasive Prenatal Testing, Chromosomal Microarray Analysis
2) By Invasive Testing: Amniocentesis, Chorionic Villus Sampling, Cordocentesis, Fetal Biopsy, Fetal Karyotyping
3) By Other Test Types: Preimplantation Genetic Testing, Targeted Gene Panels, Multiplex Polymerase Chain Reaction Testing, Fluorescence In Situ Hybridization Testing, Comparative Genomic Hybridization Testing
Who Are The Active Companies Shaping The Fetal Aneuploidy Confirmation Testing Market?
Major companies operating in the fetal aneuploidy confirmation testing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., SYNLAB AG, Myriad Genetics Inc., CapitalBio Technology Co. Ltd., BGI Genomics Co. Ltd., Centogene N.V., Yourgene Health plc, MedGenome Labs Ltd., Fulgent Genetics Inc., Annoroad Gene Technology Co. Ltd., CeGaT GmbH, LifeCodexx AG, Variantyx Inc., Igenomix S.L.U.
Get The Full Fetal Aneuploidy Confirmation Testing Market Report:
Which Region Leads The Fetal Aneuploidy Confirmation Testing Market In Terms Of Market Share?
North America was the largest region in the fetal aneuploidy confirmation testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fetal aneuploidy confirmation testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Fetal Aneuploidy Confirmation Testing Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Fetal Aneuploidy Confirmation Testing Market 2026, By The Business Research Company
pruritus therapeutic market report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
genomic urine testing market report 2026
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
ocular genetic diagnostic market report 2026
https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
